Andrew DVM - Jade Biosciences, Chief RD
| JBIO Stock | 7.29 0.40 5.81% |
Executive
Andrew DVM is Chief RD of Jade Biosciences,
| Age | 45 |
| Address | 221 Crescent Street Building 23, Waltham, MA, United States, 02453 |
| Phone | 916 322 1700 |
| Web | https://jadebiosciences.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Estes | JBG SMITH Properties | 50 | |
| Phyllis Caldwell | JBG SMITH Properties | 61 | |
| Ellen Shuman | JBG SMITH Properties | 64 | |
| Evan ReganLevine | JBG SMITH Properties | 36 | |
| Alan Forman | JBG SMITH Properties | 54 | |
| Mairead Nayager | Diageo PLC ADR | 41 | |
| Jeremy Siegfried | Rocky Brands | N/A | |
| Yashika Singh | PepsiCo | N/A | |
| Eugene Willemsen | PepsiCo | 57 | |
| Maria Sceppaguercio | Keurig Dr Pepper | 58 | |
| Carol Melton | JBG SMITH Properties | 66 | |
| Kevin Reynolds | JBG SMITH Properties | 54 | |
| Paula Santilli | PepsiCo | 60 | |
| Rebecca Schmitt | PepsiCo | 51 | |
| Timothy Cofer | Keurig Dr Pepper | 56 | |
| Seth Cohen | PepsiCo | N/A | |
| Karin RotemWildeman | Keurig Dr Pepper | 52 | |
| Angela Stephens | Keurig Dr Pepper | 57 | |
| Nicolas Quille | Crimson Wine | 50 | |
| Roberto Martinez | PepsiCo | N/A | |
| Steven Williams | PepsiCo | 59 | |
Jade Biosciences, Leadership Team
Elected by the shareholders, the Jade Biosciences,'s board of directors comprises two types of representatives: Jade Biosciences, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jade. The board's role is to monitor Jade Biosciences,'s management team and ensure that shareholders' interests are well served. Jade Biosciences,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jade Biosciences,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tom Frohlich, CEO Director | ||
| Elizabeth Balta, General Secretary | ||
| Hetal MD, Chief Officer | ||
| Jonathan Quick, Senior Finance | ||
| Andrew DVM, Chief RD | ||
| Amy Sullivan, Senior Operations | ||
| Valerie Fauvelle, Senior Quality | ||
| Bradford Dahms, Chief Officer | ||
| Lori Stewart, Senior People | ||
| Jason Wright, Chemistry and Presidentident | ||
| Sandy Lewis, Biometrics President |
Jade Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jade Biosciences, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 379.13 M | ||||
| Shares Outstanding | 32.24 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 33.33 % | ||||
| Number Of Shares Shorted | 1.87 M | ||||
| Book Value Per Share | (14.35) X | ||||
| Short Ratio | 1.20 X | ||||
| Target Price | 16.67 | ||||
| Number Of Employees | 30 | ||||
| Market Capitalization | 280.13 M |
Pair Trading with Jade Biosciences,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jade Biosciences, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jade Biosciences, will appreciate offsetting losses from the drop in the long position's value.Moving against Jade Stock
| 0.36 | VALN | Valneva SE ADR Earnings Call Next Week | PairCorr |
| 0.33 | DWTX | Dogwood Therapeutics, Symbol Change | PairCorr |
| 0.32 | DMAC | DiaMedica Therapeutics Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Jade Biosciences, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jade Biosciences, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jade Biosciences, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jade Biosciences, to buy it.
The correlation of Jade Biosciences, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jade Biosciences, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jade Biosciences, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jade Biosciences, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jade Biosciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Jade Stock, please use our How to Invest in Jade Biosciences, guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jade Biosciences,. If investors know Jade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jade Biosciences, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Jade Biosciences, is measured differently than its book value, which is the value of Jade that is recorded on the company's balance sheet. Investors also form their own opinion of Jade Biosciences,'s value that differs from its market value or its book value, called intrinsic value, which is Jade Biosciences,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jade Biosciences,'s market value can be influenced by many factors that don't directly affect Jade Biosciences,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jade Biosciences,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Jade Biosciences, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jade Biosciences,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.